Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2178-2180

  Wilson, F Perry ^a   Bachhuber, Marcus A ^a   Caroff, Daniel ^a   Adler, Rebecca ^a   Fish, Douglas ^b   Berns, Jeffrey ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTRIAXONE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTINUOUS HEMODIALYSIS; CONTROLLED STUDY; DIALYSATE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; SHOCK, CARDIOGENIC; SPECTROPHOTOMETRY, ULTRAVIOLET; YOUNG ADULT;

EID: 84858668855     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05987-11     Document Type: Article

References (9)

1. Allaouchiche B, et al. 1997. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother. 41: 2424-2427. (Pubitemid 27467551)
2. Clark WR, Turk JE. 2004. The NxStage System One. Semin. Dial. 17:167-170. (Pubitemid 38560995)
3. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. CLSI, Wayne, PA.
4. Malone RS, Fish DN, Abraham E, Teitelbaum I. 2001. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 45:3148-3155. (Pubitemid 32988842)
5. McKinnon PS, Paladino JA, Schentag JJ. 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (t>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents. 31:345-351.
6. Rabindranath K, Adams J, Macleod AM, Muirhead N. 2007. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst. Rev. CD003773.
7. Seyler L, et al. 2011. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit. Care. 15:R137.
8. Trotman RL, Williamson JC, Shoemaker MD, Salzer WL. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41:1159-1166. (Pubitemid 41429480)
9. VA/NIH Acute Renal Failure Trial Network. 2008. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359:7-20.